Sat.Sep 18, 2021 - Fri.Sep 24, 2021

article thumbnail

AstraZeneca analysed rare variant contribution to human disease

Drug Discovery Today

AstraZeneca scientists, based in Cambridge UK, have analysed over 18,000 phenotypes in combination with whole exome sequencing data from nearly 300,000 UK Biobank research participants.

Disease 113
article thumbnail

Workshop and lecture on generic portfolio management

Drug Patent Watch

I’ll be leading a workshop on generic portfolio management, and also giving a talk, at the 14th annual Marcus Evans event on Portfolio Planning and Partnerships for Generics. The event…. The post Workshop and lecture on generic portfolio management appeared first on DrugPatentWatch - Make Better Decisions.

105
105
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

How Cigna’s Growing Pharmacy Platform Expands Its Channel Power (rerun)

Drug Channels

This week, I’m rerunning some popular posts while I prepare for this Friday’s live video webinar: Drug Channels Update: Buy-and-Bill Market Trends. Click here to see the original post and comments from May 2021. Last week, Cigna released its earnings for the first quarter of 2021. Links below. I was struck by how quickly Cigna’s Express Scripts PBM business has increased revenues and prescriptions from its retail pharmacy network.

article thumbnail

Part 2 Chemistry Webinar Series: Remote Access Robotic Controlled Compound Synthesis - Recap

The Strateos Blog: Drug Discovery

On September 15th, Strateos hosted Part 2 of its Chemistry Webinar Series: Remote Access Robotic Controlled Compound Synthesis. In continued efforts to provide scientists with end-to-end technologies to accelerate their workflows, Strateos has expanded its synthetic chemistry solutions with the integration of PerkinElmer Informatics Signals™ electronic lab notebook (ELN).

article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

mRNA Vaccines – The promise of more to come

Tebu Bio: Drug Discovery

Propelled into the spotlight by the COVID-19 pandemic, mRNA has become a biological entity of great interest in drug discovery - yet mRNA vaccination is just the beginning of more and more discoveries and applications.

Vaccine 52
article thumbnail

New patent for La Jolla drug GIAPREZA

Drug Patent Watch

Annual Drug Patent Expirations for GIAPREZA Giapreza is a drug marketed by La Jolla Pharma and is included in one NDA. It is available from one supplier. There are eight…. The post New patent for La Jolla drug GIAPREZA appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 95

More Trending

article thumbnail

The Principles of Exempted Devices

Pharmaceutical Development Group

Introduction: Devices exempted under 510(k) state if the device offers safety and is highly effective on the consumers under the FDA. Exempted Devices which get relaxation by 510(k) are classified by the FDA into Class I type, Class II type, and Class III type. There are specific regulations mentioned with each generic type of device. The classification regulations, however, come over various categories of devices.

FDA 52
article thumbnail

New patent for NOVO drug SAXENDA

Drug Patent Watch

Annual Drug Patent Expirations for SAXENDA Saxenda is a drug marketed by Novo and is included in one NDA. It is available from two suppliers. There are twenty-two patents protecting…. The post New patent for NOVO drug SAXENDA appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 90
article thumbnail

DCI’s Top 15 Specialty Pharmacies of 2020: PBMs Expand Amid the Shakeout—While Walgreens’ Outlook Dims (rerun)

Drug Channels

This week, I’m rerunning some popular posts while I prepare for this Friday’s live video webinar: Drug Channels Update: Buy-and-Bill Market Trends. Click here to see the original post and comments from May 2021. BTW, my prediction about AllianceRx Walgreens Prime is already starting to come true. Prime Therapeutics recently alleged that Walgreens is competing against the companies' joint venture.

article thumbnail

Pharmacist Job Market in 2020: Hospital Employment Up, Retail Salaries Down (rerun)

Drug Channels

This week, I’m rerunning some popular posts while I prepare for today's live video webinar: Drug Channels Update: Buy-and-Bill Market Trends. Click here to see the original post and comments from June 2021. The Bureau of Labor Statistics (BLS) has recently released its employment and salary data for 2020. That means it’s time to update Drug Channels Institute’s (DCI) annual analysis of pharmacist salaries and employment.

article thumbnail

Deliver Fast, Flexible Clinical Trial Insights with Spotfire

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

article thumbnail

New patent for Vero Biotech drug GENOSYL

Drug Patent Watch

Annual Drug Patent Expirations for GENOSYL Genosyl is a drug marketed by Vero Biotech and is included in one NDA. There are nineteen patents protecting this drug. This drug has…. The post New patent for Vero Biotech drug GENOSYL appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52
article thumbnail

New patent for Therapeuticsmd Inc drug IMVEXXY

Drug Patent Watch

Annual Drug Patent Expirations for IMVEXXY Imvexxy is a drug marketed by Therapeuticsmd Inc and is included in one NDA. It is available from one supplier. There are twelve patents…. The post New patent for Therapeuticsmd Inc drug IMVEXXY appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52
article thumbnail

New patent for Nalpropion drug CONTRAVE

Drug Patent Watch

Annual Drug Patent Expirations for CONTRAVE Contrave is a drug marketed by Nalpropion and is included in one NDA. It is available from three suppliers. There are fourteen patents protecting…. The post New patent for Nalpropion drug CONTRAVE appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52
article thumbnail

New patent for Ipsen Inc drug ONIVYDE

Drug Patent Watch

Annual Drug Patent Expirations for ONIVYDE Onivyde is a drug marketed by Ipsen Inc and is included in one NDA. It is available from one supplier. There are sixteen patents…. The post New patent for Ipsen Inc drug ONIVYDE appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52
article thumbnail

Clinical Data Like You´ve Never Seen It Before: Why Spotfire Is the Leading Tool for Clinical Analytics

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

article thumbnail

New patent for Currax drug SILENOR

Drug Patent Watch

Annual Drug Patent Expirations for SILENOR Silenor is a drug marketed by Currax and is included in one NDA. It is available from three suppliers. There are twelve patents protecting…. The post New patent for Currax drug SILENOR appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52
article thumbnail

New patent for Therapeuticsmd Inc drug BIJUVA

Drug Patent Watch

Annual Drug Patent Expirations for BIJUVA Bijuva is a drug marketed by Therapeuticsmd Inc and is included in one NDA. It is available from one supplier. There are sixteen patents…. The post New patent for Therapeuticsmd Inc drug BIJUVA appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52
article thumbnail

New patent for Vifor Pharma drug VELTASSA

Drug Patent Watch

Annual Drug Patent Expirations for VELTASSA Veltassa is a drug marketed by Vifor Pharma and is included in one NDA. It is available from one supplier. There are twelve patents…. The post New patent for Vifor Pharma drug VELTASSA appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52
article thumbnail

New patent for Janssen Pharms drug XARELTO

Drug Patent Watch

Annual Drug Patent Expirations for XARELTO Xarelto is a drug marketed by Janssen Pharms and is included in one NDA. It is available from three suppliers. There are four patents…. The post New patent for Janssen Pharms drug XARELTO appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52
article thumbnail

New patent for Amarin Pharms drug VASCEPA

Drug Patent Watch

Annual Drug Patent Expirations for VASCEPA Vascepa is a drug marketed by Amarin Pharms and is included in one NDA. It is available from two suppliers. There are sixty-three patents…. The post New patent for Amarin Pharms drug VASCEPA appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52
article thumbnail

New patent for NOVO drug OZEMPIC

Drug Patent Watch

Annual Drug Patent Expirations for OZEMPIC Ozempic is a drug marketed by Novo and is included in one NDA. It is available from three suppliers. There are twenty-two patents protecting…. The post New patent for NOVO drug OZEMPIC appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52
article thumbnail

New patent for Novartis drug MAYZENT

Drug Patent Watch

Annual Drug Patent Expirations for MAYZENT Mayzent is a drug marketed by Novartis and is included in one NDA. It is available from one supplier. There are two patents protecting…. The post New patent for Novartis drug MAYZENT appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52
article thumbnail

New patent expiration for Novadaq Tech drug SPY AGENT GREEN KIT

Drug Patent Watch

Annual Drug Patent Expirations for SPY+AGENT+GREEN+KIT Spy Agent Green Kit is a drug marketed by Novadaq Tech and is included in one NDA. It is available from one supplier. There…. The post New patent expiration for Novadaq Tech drug SPY AGENT GREEN KIT appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52
article thumbnail

New patent for Institut Biochimique drug TIROSINT-SOL

Drug Patent Watch

Annual Drug Patent Expirations for TIROSINT-SOL Tirosint-sol is a drug marketed by Institut Biochimique and is included in one NDA. There is one patent protecting this drug. This drug has…. The post New patent for Institut Biochimique drug TIROSINT-SOL appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52
article thumbnail

New patent expiration for Sun Pharm drug ABSORICA

Drug Patent Watch

Annual Drug Patent Expirations for ABSORICA Absorica is a drug marketed by Sun Pharm Inds Inc and Sun Pharm and is included in two NDAs. It is available from one…. The post New patent expiration for Sun Pharm drug ABSORICA appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52
article thumbnail

EXCLUSIVE: The 340B Program Soared to $38 Billion in 2020—Up 27% vs. 2019 (rerun)

Drug Channels

This week, I’m rerunning some popular posts while I prepare for this Friday’s live video webinar: Drug Channels Update: Buy-and-Bill Market Trends. Click here to see the original post and comments from June 2021. Despite what you may have heard, the 340B Drug Pricing Program continues to thrive. Discounted purchases under the program reached at least $38 billion in 2020.

article thumbnail

Drug Patent Expirations for the Week of September 19, 2021

Drug Patent Watch

ABSORICA (isotretinoin) Sun pharm inds inc Patent: 9,089,534 Expiration: Sep 21, 2021 See More … For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact…. The post Drug Patent Expirations for the Week of September 19, 2021 appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 40
article thumbnail

Which pharmaceutical companies have the most SPCs in Finland?

Drug Patent Watch

This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in Finland. SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating…. The post Which pharmaceutical companies have the most SPCs in Finland? appeared first on DrugPatentWatch - Make Better Decisions.

article thumbnail

Which pharmaceutical companies have the most SPCs in Spain?

Drug Patent Watch

This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in Spain. SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating…. The post Which pharmaceutical companies have the most SPCs in Spain? appeared first on DrugPatentWatch - Make Better Decisions.

article thumbnail

Which pharmaceutical companies have the most drug patents in Hungary?

Drug Patent Watch

This chart shows the pharmaceutical companies with the most patents in Hungary. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical companies have the most drug patents in Hungary? appeared first on DrugPatentWatch - Make Better Decisions.

article thumbnail

Which pharmaceutical companies have the most drug patents in China?

Drug Patent Watch

This chart shows the pharmaceutical companies with the most patents in China. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical companies have the most drug patents in China? appeared first on DrugPatentWatch - Make Better Decisions.

article thumbnail

Injectable dosed drug patent expirations by year

Drug Patent Watch

This chart shows the patent expirations for injectable dosed drugs over the next decade. The term of drug patents varies. The basic term for a patent is 20 years from…. The post Injectable dosed drug patent expirations by year appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52
article thumbnail

Which pharmaceutical companies have the most drug patents in Czech Republic?

Drug Patent Watch

This chart shows the pharmaceutical companies with the most patents in Czech Republic. Patents must be filed in each country (or, in some cases regional patent office) where patent protection…. The post Which pharmaceutical companies have the most drug patents in Czech Republic? appeared first on DrugPatentWatch - Make Better Decisions.

article thumbnail

Which pharmaceutical drugs have the most drug patents in Switzerland?

Drug Patent Watch

This chart shows the drugs with the most patents in Switzerland. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.…. The post Which pharmaceutical drugs have the most drug patents in Switzerland? appeared first on DrugPatentWatch - Make Better Decisions.